CStore Decisions

  • Home
  • Today on CSD
  • Categories
    • CBD
    • Foodservice
    • Fuel & Gas
    • Health & Beauty
    • Independent Operators
    • Operations & Marketing
    • Technology
  • CStore Playbooks
    • Alcoholic Beverage Playbook
    • Candy Playbook
    • CBD Playbook
    • Foodservice Playbook
    • Technology Playbook
    • Tobacco Playbook
  • Products
    • 2022 Hot New Product Contest
    • Hot New Products Contest
    • Beverages & Cold Vault
    • Candy, Gum & Mints
    • Snacks
    • Tobacco
  • Resources
    • Digital Issues
    • Research & Downloads
    • Podcasts/How To Series
    • On Location
    • FAQ
    • 2022 Top 111 Chains
    • Leaders in Convenience
    • Rack Prices
    • Sponsored Content
    • Videos
    • Webinars / Digital Events
    • White Papers
  • Events
    • 2022 Chain of the Year
    • Convenience Directions
    • NAG Convenience Conference
    • Young Executive Organization
  • Join
    • National Advisory Group
    • Safe Shop Assured
    • Young Executive Organization

22nd Century Offers Clinical Trial Update

By CSD Staff | October 11, 2016

Share

22nd century group logo-resized-600 copyNames 10 major research centers as study locations in very low nicotine content tobacco cigarette clinical trial.

22nd Century Group Inc. announced that an update has been issued on the pivotal Phase III study entitled “Strategies for Reducing Nicotine Content in Cigarettes.”

Funded by the National Institutes of Health (NIH) and led by Eric Donny, Ph.D. of the University of Pittsburgh, this highly significant clinical trial will determine whether the harm caused by smoking is most effectively addressed by either 22nd Century’s proprietary Very Low Nicotine Content tobacco cigarettes (95% less nicotine than conventional cigarettes), or 22nd Century’s proprietary SPECTRUM tobacco cigarettes that contain progressively lower nicotine content.

The clinical trial update names 10 nationally recognized research centers, including the Mayo Clinic, the MD Anderson Cancer Center, Duke University, Johns Hopkins University, the Moffitt Cancer Center, and the University of California San Francisco. With an estimated enrollment of 1,250 patients, the on-going study is expected to be completed in March 2017. The Company expects the results of this study to accelerate the governmental approval process of the Company’s “X-22” smoking cessation product so that millions of lives and billions in healthcare costs can be saved each year.

“By evaluating 22nd Century’s Very Low Nicotine cigarettes against 22nd Century’s gradually reduced nicotine cigarettes, the Donny trial recognizes that reducing smokers’ exposure to nicotine is a vital public health goal. Contrary to false and misleading information recently disseminated by short-sellers of 22nd Century stock, we are confident that our patented technologies will produce multi-billion dollar products in both the tobacco and the pharmaceutical industries,” explained Henry Sicignano, III, president and CEO of 22nd Century Group. “Our Company is recognized by the National Institute of Health, the World Health Organization, and public health advocates around the world as absolutely key to reducing smokers’ exposure to nicotine; independent clinical studies continue to show that our Very Low Nicotine cigarettes have the potential to greatly impact public health.”

 

 

Related Articles Read More >

Go Time Offers Personal Service with a Small-Town Feel
Contactless Payment Transactions Continue to Increase
Wawa Releases Video with Philadelphia Eagles Players
Black Buffalo Completes $30 Million Equity Raise
Safe Shop Assured

CStore Decisions Newsletter

Sponsored Content

  • Create Some Positivity at the Pump: 3 Ways to Fuel Customer Experiences
  • How Minuteman Food Mart Ensures a Consistent Customer Experience Across 44 Stores
  • Three Challenges Disrupting C-Store Operations and How to Overcome Them
  • Why Wait? Converting to E15 is easy.
  • It’s time you profited from your checkout line

Get the Magazine

Subscribe Now!
Subscribe Now!

Manage Current Subscription
CStore Decisions
  • New CSD Print Subscription
  • Manage current print subscription
  • CBD Retail Trends
  • CStore Products
  • NAG Convenience Conference
  • Convenience Directions
  • Rack Prices
  • Subscribe to CSD’s E-Newsletter
  • About CStore Decisions
  • Advertise

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search CStore Decisions

  • Home
  • Today on CSD
  • Categories
    • CBD
    • Foodservice
    • Fuel & Gas
    • Health & Beauty
    • Independent Operators
    • Operations & Marketing
    • Technology
  • CStore Playbooks
    • Alcoholic Beverage Playbook
    • Candy Playbook
    • CBD Playbook
    • Foodservice Playbook
    • Technology Playbook
    • Tobacco Playbook
  • Products
    • 2022 Hot New Product Contest
    • Hot New Products Contest
    • Beverages & Cold Vault
    • Candy, Gum & Mints
    • Snacks
    • Tobacco
  • Resources
    • Digital Issues
    • Research & Downloads
    • Podcasts/How To Series
    • On Location
    • FAQ
    • 2022 Top 111 Chains
    • Leaders in Convenience
    • Rack Prices
    • Sponsored Content
    • Videos
    • Webinars / Digital Events
    • White Papers
  • Events
    • 2022 Chain of the Year
    • Convenience Directions
    • NAG Convenience Conference
    • Young Executive Organization
  • Join
    • National Advisory Group
    • Safe Shop Assured
    • Young Executive Organization